Literature DB >> 15653989

Cytomegalovirus infection in critically ill patients: associated factors and consequences.

Samir Jaber1, Gérald Chanques, Jean Borry, Bruno Souche, Régis Verdier, Pierre-François Perrigault, Jean-Jacques Eledjam.   

Abstract

OBJECTIVE: To determine the prevalence, associated findings, and consequences of cytomegalovirus (CMV) antigenemia in critically ill patients.
DESIGN: A retrospective, case-control clinical study.
SETTING: A 12-bed university hospital medical-surgical ICU. PATIENTS: Two hundred thirty-seven patients with fever for > 72 h, without proven evidence of bacteriologic and/or fungal origin, and whose pp65 antigenemia assays were studied. Patients with HIV infection and transplant recipients were excluded.
INTERVENTIONS: None. MEASUREMENTS AND
RESULTS: CMV antigenemia was diagnosed within 20 +/- 12 days (mean +/- SD) after ICU admission in 17% patients in whom the pathology was suspected. The 40 patients in the CMV group were matched with 40 other patients in the control group. CMV infection was linked to renal failure (58% vs 33%, respectively; p = 0.02) and steroid use (55% vs 33%, respectively; p = 0.04). Patients with CMV had a significantly longer stay in the ICU (41 +/- 28 days vs 31 +/- 22 days, respectively; p = 0.04), a longer duration of mechanical ventilation (35 +/- 27 days vs 24 +/- 20 days, respectively; p = 0.03), a higher rate of nosocomial infection (75% vs 50%, respectively; p = 0.04), and a higher mortality (50% vs 28%, p = 0.02).
CONCLUSIONS: CMV antigenemia is not an uncommon diagnosis in critically ill ICU patients with unexplained prolonged fever after 10 days of hospitalization, regardless of their immune system status. Although associated with a higher morbidity and mortality, the clinical significance of CMV is unknown. Further prospective studies should evaluate the impact on ICU outcome and whether CMV is truly a pathogen or simply another indicator of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653989     DOI: 10.1378/chest.127.1.233

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  54 in total

1.  Cytomegalovirus and Epstein-Barr virus reactivation in the intensive care unit.

Authors:  O Coşkun; E Yazici; F Şahiner; A Karakaş; S Kiliç; M Tekin; C Artuk; L Yamanel; B A Beşirbellioğlu
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-19       Impact factor: 0.840

2.  Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice.

Authors:  Charles H Cook; Joanne Trgovcich; Peter D Zimmerman; Yingxue Zhang; Daniel D Sedmak
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: con.

Authors:  G Chanques; S Jaber
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

4.  Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: pro.

Authors:  Jean-Marie Forel; Ignacio Martin-Loeches; Charles-Edouard Luyt
Journal:  Intensive Care Med       Date:  2014-11-01       Impact factor: 17.440

Review 5.  Impact of cytomegalovirus load on host response to sepsis.

Authors:  Thomas Marandu; Michael Dombek; Charles H Cook
Journal:  Med Microbiol Immunol       Date:  2019-04-11       Impact factor: 3.402

6.  Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.

Authors:  Meghan R Forster; Joanne Trgovcich; Peter Zimmerman; Alexander Chang; Cortland Miller; Paul Klenerman; Charles H Cook
Journal:  Antiviral Res       Date:  2009-12-11       Impact factor: 5.970

7.  Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies.

Authors:  Ayumi K Shintani; Timothy D Girard; Svetlana K Eden; Patrick G Arbogast; Karel G M Moons; E Wesley Ely
Journal:  Crit Care Med       Date:  2009-11       Impact factor: 7.598

8.  Cytomegalovirus in the intensive care unit: pathogen or passenger?

Authors:  Jeffrey I Cohen
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

9.  Highly quantitative serological detection of anti-cytomegalovirus (CMV) antibodies.

Authors:  Peter D Burbelo; Alexandra T Issa; Kathryn H Ching; Maurice Exner; W Lawrence Drew; Harvey J Alter; Michael J Iadarola
Journal:  Virol J       Date:  2009-05-01       Impact factor: 4.099

Review 10.  Cytomegalovirus infection in critically ill patients: a systematic review.

Authors:  Ryosuke Osawa; Nina Singh
Journal:  Crit Care       Date:  2009-05-14       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.